Role of Spleen Tyrosine Kinase in Liver Diseases

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2020 Mar 25

PMID 32205992

Citations 9

Authors

Dhadhang Wahyu Kurniawan

Gert Storm

Jai Prakash

Ruchi Bansal

Affiliations

Soon will be listed here.

Abstract

Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase expressed in most hematopoietic cells and non-hematopoietic cells and play a crucial role in both immune and non-immune biological responses. SYK mediate diverse cellular responses an immune-receptor tyrosine-based activation motifs (ITAMs)-dependent signalling pathways, ITAMs-independent and ITAMs-semi-dependent signalling pathways. In liver, SYK expression has been observed in parenchymal (hepatocytes) and non-parenchymal cells (hepatic stellate cells and Kupffer cells), and found to be positively correlated with the disease severity. The implication of SYK pathway has been reported in different liver diseases including liver fibrosis, viral hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis and hepatocellular carcinoma. Antagonism of SYK pathway using kinase inhibitors have shown to attenuate the progression of liver diseases thereby suggesting SYK as a highly promising therapeutic target. This review summarizes the current understanding of SYK and its therapeutic implication in liver diseases.

Citing Articles

Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease.

Zhang L, Liu S, Zhao Q, Liu X, Liu T, Zhang Q World J Hepatol. 2025; 17(2):102328.

PMID: 40027566 PMC: 11866134. DOI: 10.4254/wjh.v17.i2.102328.

Neuronal-specific methylome and hydroxymethylome analysis reveal significant loci associated with alcohol use disorder.

Andrade-Brito D, Nunez-Rios D, Martinez-Magana J, Nagamatsu S, Rompala G, Zillich L Front Genet. 2024; 15:1345410.

PMID: 38633406 PMC: 11021708. DOI: 10.3389/fgene.2024.1345410.

Neuronal-specific methylome and hydroxymethylome analysis reveal replicated and novel loci associated with alcohol use disorder.

Andrade-Brito D, Nunez-Rios D, Martinez-Magana J, Nagamatsu S, Rompala G, Zillich L medRxiv. 2023; .

PMID: 38105948 PMC: 10725575. DOI: 10.1101/2023.11.28.23299094.

Exploring Key Genes with Diagnostic Value for Nonalcoholic Steatohepatitis Based on Bioinformatics Analysis.

Zeng W, Xu X, Xu F, Zhu F, Li Y, Ma J ACS Omega. 2023; 8(23):20959-20967.

PMID: 37323410 PMC: 10268261. DOI: 10.1021/acsomega.3c01709.

Exploration of the mechanism of NORAD activation of TGF-β1/Smad3 through miR-136-5p and promotion of tacrolimus-induced renal fibrosis.

Liu L, Guo J, Pang X, Shang W, Wang Z, Wang J Ren Fail. 2023; 45(1):2147083.

PMID: 36748746 PMC: 9930837. DOI: 10.1080/0886022X.2022.2147083.

References

Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney S, Ives D . Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2011; 340(2):350-9. DOI: 10.1124/jpet.111.188441. View

Szabo G, Csak T . Inflammasomes in liver diseases. J Hepatol. 2012; 57(3):642-54. DOI: 10.1016/j.jhep.2012.03.035. View

Wossning T, Herzog S, Kohler F, Meixlsperger S, Kulathu Y, Mittler G . Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med. 2006; 203(13):2829-40. PMC: 2118175. DOI: 10.1084/jem.20060967. View

Yoshimoto T, Hayashi T, Kondo T, Kittaka M, Reichenberger E, Ueki Y . Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model. J Bone Miner Res. 2018; 33(8):1513-1519. PMC: 6351076. DOI: 10.1002/jbmr.3449. View

Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A . Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. Oncotarget. 2015; 6(41):43881-96. PMC: 4791274. DOI: 10.18632/oncotarget.6316. View

Mehal W . The inflammasome in liver injury and non-alcoholic fatty liver disease. Dig Dis. 2014; 32(5):507-15. DOI: 10.1159/000360495. View

Afifiyan N, Tillman B, French B, Sweeny O, Masouminia M, Samadzadeh S . The role of Tec kinase signaling pathways in the development of Mallory Denk Bodies in balloon cells in alcoholic hepatitis. Exp Mol Pathol. 2017; 103(2):191-199. PMC: 5680109. DOI: 10.1016/j.yexmp.2017.09.001. View

Gao B, Bataller R . Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011; 141(5):1572-85. PMC: 3214974. DOI: 10.1053/j.gastro.2011.09.002. View

Song I, Yang Y, Inokuchi-Shimizu S, Roh Y, Yang L, Seki E . The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 2017; 142(1):81-91. PMC: 5790193. DOI: 10.1002/ijc.31029. View

10.

Chaudhary A, Fresquez T, Naranjo M . Tyrosine kinase Syk associates with toll-like receptor 4 and regulates signaling in human monocytic cells. Immunol Cell Biol. 2007; 85(3):249-56. DOI: 10.1038/sj.icb7100030. View

11.

Dunn W, Shah V . Pathogenesis of Alcoholic Liver Disease. Clin Liver Dis. 2016; 20(3):445-56. PMC: 4933837. DOI: 10.1016/j.cld.2016.02.004. View

12.

Zekri A, Hafez M, Bahnassy A, Hassan Z, Mansour T, Kamal M . Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: preliminary study. BMC Res Notes. 2008; 1:106. PMC: 2584108. DOI: 10.1186/1756-0500-1-106. View

13.

Mridha A, Wree A, Robertson A, Yeh M, Johnson C, Van Rooyen D . NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017; 66(5):1037-1046. PMC: 6536116. DOI: 10.1016/j.jhep.2017.01.022. View

14.

Burke J, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R . An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18(8):e327-e331. PMC: 6857170. DOI: 10.1016/j.clml.2018.05.022. View

15.

Kulathu Y, Hobeika E, Turchinovich G, Reth M . The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J. 2008; 27(9):1333-44. PMC: 2374840. DOI: 10.1038/emboj.2008.62. View

16.

Lucas M, Bhagirath N, Chiao E, Goldstein D, Hermann J, Hsu P . Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors. J Med Chem. 2014; 57(6):2683-91. DOI: 10.1021/jm401982j. View

17.

Keshvara L, Isaacson C, Harrison M, Geahlen R . Syk activation and dissociation from the B-cell antigen receptor is mediated by phosphorylation of tyrosine 130. J Biol Chem. 1997; 272(16):10377-81. DOI: 10.1074/jbc.272.16.10377. View

18.

Mao Y, Yu F, Wang J, Guo C, Fan X . Autophagy: a new target for nonalcoholic fatty liver disease therapy. Hepat Med. 2016; 8:27-37. PMC: 4822806. DOI: 10.2147/HMER.S98120. View

19.

Aouar B, Kovarova D, Letard S, Font-Haro A, Florentin J, Weber J . Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. PLoS One. 2016; 11(6):e0156063. PMC: 4892542. DOI: 10.1371/journal.pone.0156063. View

20.

Carone C, Olivani A, Dalla Valle R, Manuguerra R, Silini E, Trenti T . Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence. Liver Cancer. 2018; 7(3):277-294. PMC: 6167723. DOI: 10.1159/000486764. View